ArticleClinical research in cardiology : official journal of the German Cardiac Society2023
Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction ("Jena auf Ziel").
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Guideline
- Residual atherosclerotic cardiovascular disease risk in statin-treated patients: mechanisms, therapeutic strategies, and future directions-a scoping review.Frontiers in cardiovascular medicine · 2026Pooled it
- The role of early ezetimibe combination with atorvastatin in patients with atherosclerotic cardiovascular disease.BMC cardiovascular disorders · 2026Trial
- Article
- Systematic literature review on the real-world effectiveness and safety of bempedoic acid.Atherosclerosis plus · 2026Review
- Article
- Real-world experience in the management of lipids in patients after an acute coronary syndrome.Journal of Taibah University Medical Sciences · 2026Article
- Goal Attainment Rate in Secondary Prevention in Taiwan - A Chang Gung Research Database Study.Acta Cardiologica Sinica · 2026Article
- Combination Lipid-Lowering Therapy After ACS: Should this be the New Standard of Care?Current cardiology reports · 2026Review
- Effects of high- versus low-intensity lipid-lowering treatment in patients undergoing serial coronary computed tomography angiography: results of the multi-center LOCATE study.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- A call for high-intensity lipid-lowering treatment of ASCVD patients diagnosed by coronary computed tomography angiography: lessons from the multi-center LOCATE study.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- The lipid card in cardiovascular patients: early enthusiasm but limited long-term use.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Less intensive lipid-lowering therapy after ST-elevation myocardial infarction is associated with cardiovascular events: 2-year follow-up of "Jena auf Ziel".Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- LipidSnapshot - Treatment gaps in hypercholesterolemia in patients with atherosclerotic cardiovascular disease documented by office-based cardiologists and general practitioners in Germany.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Prevalence of elevated lipoprotein(a) in cardiac rehabilitation patients - results from a large-scale multicentre registry in Germany.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- A practical guide to the management of dyslipidaemia.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Review
- Early escalation of oral lipid-lowering therapy to achieve LDL-cholesterol targets in patients after myocardial infarction: study protocol for the prospective, open-label HAnnover ChOlesterol Lowering in Acute Coronary Syndrome trial.Frontiers in cardiovascular medicine · 2026Article
- Performance of Cardiovascular Disease (CVD) Risk Assessment Tools in Clinical Practice - Agreement Between Different CVD Risk Scores Among Patients Attending NCD Clinic in a Tertiary Care Setting: A Prospective Observational Study.International journal of preventive medicine · 2026Article
- Predictors of Escalation of Lipid-Lowering Therapy with Subanalysis of the Influence of Lipoprotein (a) on the Decision-Making Process.Diseases (Basel, Switzerland) · 2025Article
- Effectiveness and Safety of Very-Low-Dose Rosuvastatin-Ezetimibe Therapy in Korean Patients with Dyslipidaemia: A Multicentre Prospective Observational Study.Clinical drug investigation · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsCurrently, less than 20% of patients at very high-risk achieve ESC/EAS dyslipidemia guideline-recommended LDL-C target levels in Europe. "Jena auf Ziel-JaZ" is a prospective cohort study in which early combination therapy with atorvastatin 80 mg and ezetimibe 10 mg was initiated on admission in patients with ST-elevation myocardial infarction (STEMI) and lipid-lowering therapy was escalated during follow-up with bempedoic acid and PCSK9 inhibitors to achieve recommended LDL-C targets in all patients. Moreover, we evaluated side-effects of lipid-lowering therapy.
methodsPatients admitted with STEMI at Jena University Hospital were started on atorvastatin 80 mg and ezetimibe 10 mg on admission. Patients were followed for EAS/ESC LDL-C target achievement during follow-up.
resultsA total of 85 consecutive patients were enrolled in the study. On discharge, 32.9% achieved LDL-C targets on atorvastatin 80 mg and ezetimibe 10 mg. After 4-6 weeks, 80% of all patients on atorvastatin 80 mg and ezetimibe started at the index event were on ESC/EAS LDL-C targets. In 20%, combined lipid-lowering therapy was escalated with either bempedoic acid or PCSK9 inhibitors. All patients achieved LDL-C levels of or below 55 mg/dL during follow-up on triple lipid-lowering therapy. Combined lipid-lowering therapy was well-tolerated with rare side effects.
conclusionsEarly combination therapy with a high-intensity statin and ezetimibe and escalation of lipid-lowering therapy with either bempedoic acid or PCSK9 inhibitors gets potentially all patients with STEMI on recommended ESC/EAS LDL-C targets without significant side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.